Valuation: MBX Biosciences, Inc.

Market Cap 2.72B 2.42B 2.26B 2.06B 3.88B 262B 3.93B 27.37B 10.59B 134B 10.23B 10B 429B P/E 2026 *
-18.2x
P/E 2027 * -14x
Enterprise Value 2.21B 1.97B 1.84B 1.67B 3.15B 213B 3.2B 22.24B 8.61B 109B 8.31B 8.13B 348B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.18%
Yield 2026 *
-
Yield 2027 * -
1 day-3.53%
1 week+2.09%
Current month-3.53%
1 month-7.19%
3 months+1.13%
6 months+75.13%
Current year+79.30%
1 week 52.59
Extreme 52.5945
60.2
1 month 52.32
Extreme 52.32
65
Current year 26.14
Extreme 26.14
72.64
1 year 12.94
Extreme 12.94
72.64
3 years 4.81
Extreme 4.8069
72.64
5 years 4.81
Extreme 4.8069
72.64
10 years 4.81
Extreme 4.8069
72.64
Manager TitleAgeSince
Chief Executive Officer 55 13/07/2026
Director of Finance/CFO 73 01/03/2026
Chief Tech/Sci/R&D Officer - 23/06/2025
Director TitleAgeSince
Director/Board Member 66 01/07/2020
Director/Board Member 55 01/07/2020
Director/Board Member 69 05/04/2022
Date Insider Type Main position Quantity % Market Cap. Importance
04/08/26 Sell

Chief Technology Officer

-370 0.0008%
03/08/26 Free

Chief Financial Officer

158,000 0.3281%
03/08/26 Free

Chief Executive Officer

402,000 0.8347%
Change 5-day change 1-year change 3-year change Capi.($)
-3.53%+2.09%+215.92% - 2.72B
+4.16%+3.04%+49.37%+94.17% 74.41B
-0.61%+0.81%+27.25%+82.72% 59.26B
-2.54%-1.65%+4.86%+31.72% 47.14B
-3.02%-5.20%+27.94%+32.51% 42.91B
+0.31%+3.02%+348.95%+643.82% 44.13B
-1.96%-0.33%+7.04%+99.46% 40.79B
+3.32%+3.49%+10.10%+51.23% 30.77B
-3.57%+2.26%+28.80%+21.93% 29.31B
-4.86%-10.66%-26.27%+330.06% 23.71B
Average -1.20%-0.26%+69.40%+154.18% 39.52B
Weighted average by Cap. -0.41%-0.30%+59.53%+146.05%

Financials

2026 *2027 *
Net sales - -
Net income -151M -134M -125M -114M -215M -14.51B -218M -1.51B -586M -7.39B -566M -553M -23.73B -220M -195M -183M -167M -314M -21.18B -318M -2.21B -856M -10.79B -826M -808M -34.65B
Net Debt -511M -454M -424M -387M -728M -49.17B -738M -5.13B -1.99B -25.04B -1.92B -1.88B -80.43B -418M -372M -347M -317M -596M -40.28B -604M -4.2B -1.63B -20.51B -1.57B -1.54B -65.89B
Logo MBX Biosciences, Inc.
MBX Biosciences, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP platform, for the treatment of endocrine and metabolic disorders. It is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets and proven endpoints for regulatory approval. Its pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism in Phase III development and an obesity portfolio that includes MBX 4291 in Phase I development and MBX 5765 and MBX 6180 in preclinical development, as well as additional discovery candidates. Its lead obesity product candidate, MBX 4291, is designed to be a long-acting and highly potent glucagon-like peptide 1 (GLP-1) / glucose-dependent insulinotropic polypeptide (GIP) co-agonist prodrug with the goal of potential once-monthly dosing frequency.
Employees
63
Date Price Change Volume
01/10/26 $56.55 -3.53% 434,148
30/09/26 $58.62 +1.51% 523,792
29/09/26 $57.75 +0.36% 357,124
28/09/26 $57.54 +7.29% 439,612
25/09/26 $53.63 -3.18% 563,530
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
56.55USD
Average target price
88.10USD
Spread / Average Target
+55.79%

Quarterly revenue - Rate of surprise